丹参酮ⅡA对小鼠Lewis肺癌获得性多药耐药及相关酶系影响的实验研究  

Tanshinone Ⅱ A on mice Lewis lung cancer and acquired multidrug resistance related enzymes in rats

作　　者：何欣[1] 曾柏荣[1] 刘华[1] 

机构地区：[1]湖南中医药大学第一附属医院,湖南长沙410007

出　　处：《中医药导报》2010年第9期89-91,共3页Guiding Journal of Traditional Chinese Medicine and Pharmacy

基　　金：湖南省科学技术厅基金资助项目(湘科条字[2006]163号);湖南省中医药管理局科研基金项目(2008100)

摘　　要：目的:观察丹参酮ⅡA对化疗诱导的小鼠Lewis获得性多药耐药(MDR)模型化疗敏感性及对P-糖蛋白(P-gp)、拓扑异构酶Ⅱ(TOPOⅡ)的影响。方法:采用体外培养的方法建立耐阿霉素(ADM)Lewis肺癌细胞株,皮下注射复制肿瘤获得性多药耐药模型,分组给予化疗药环磷酰胺(CTX)及丹参酮ⅡA 4周,观察各组瘤体大小,计算抑瘤率。流式细胞仪荧光检测干预后MDR肿瘤细胞凋亡及P-gp、TOPOⅡ表达变化。结果:丹参酮ⅡA能显著提高CTX的抑瘤率及肿瘤细胞凋亡,降低P-gp、TOPOⅡ表达。结论:丹参酮ⅡA有逆转小鼠Lewis肺癌获得性多药耐药的作用,可能与降低P-gp、TOPOⅡ表达有关。Objective： To observe the tanshinone Ⅱ A on chemotherapy-induced mouse Lewis acquired multidrug resistance（MDR） model and the chemotherapy sensitivity of P-glycoprotein（P-gp）,topoisomerase Ⅱ（TOPO Ⅱ） of.Methods： The in vitro method to establish resistance to adriamycin（ADM） Lewis lung cancer cell lines,subcutaneous injection of tumor-acquired multidrug resistance model,group given chemotherapy drug cyclophosphamide（CTX） and tanshinone Ⅱ A 4 weeks,and the group tumor size,tumor inhibition rate.Fluorescence flow cytometry after the intervention of MDR tumor cell apoptosis and P-gp,TOPO Ⅱ expression.Results： tanshinone Ⅱ A can significantly increase the inhibition rate of CTX and tumor cell apoptosis,decreased P-gp,TOPO Ⅱ expression.Conclusion： tanshinone Ⅱ A reversal of murine Lewis lung cancer has acquired the role of multidrug resistance,which may reduce P-gp,TOPO Ⅱ expression.

关 键 词：获得性多药耐药 丹参酮ⅡA P-糖蛋白 拓扑异构酶Ⅱ 

分 类 号：R285.5[医药卫生—中药学]